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  EVIDENCE-BASED ANSWER 
Evidence is conflicting regarding the risk of cardiovascular complications from white-coat hypertension. Some 
but not all studies show lower cardiovascular event rates for patients with white-coat hypertension compared 
with those with sustained hypertension (strength of recommendation [SOR]: B, cohort studies with conflicting 
results and methodological problems). 
Little information is available about the use of antihypertensive medication for white-coat hypertension. In 1 
small randomized trial, the difference in stroke incidence and cardiovascular complications between active 
treatment and placebo did not reach statistical significance (SOR: B, based on an underpowered randomized 
controlled trial). Some experts recommend that patients with white-coat hypertension should be evaluated for 
evidence of target organ injury and monitored for the development of sustained hypertension (SOR: C, expert 
opinion). 
  EVIDENCE SUMMARY 
A prospective cohort study compared cardiovascular events among patients with white-coat hypertension vs 
those with sustained hypertension. The study evaluated 479 patients with persistently elevated clinic systolic 
blood pressures of 140 to 180 mm Hg. Using 24-hour intraarterial ambulatory blood pressure monitoring 
(ABPM), they found that 126 patients had ambulatory blood pressures below 140/90 mm Hg (white-coat 
hypertension) while 353 patients maintained pressures above 140/90 mm Hg (sustained hypertension). On 
average, white-coat hypertension patients were younger than sustained hypertension patients (44 vs 52 years) 
but were otherwise similar. Over the next 9 years, patients with white-coat hypertension had significantly fewer 
cardiovascular events than patients with sustained hypertension ( Table ).1 
Another prospective cohort study compared fatal and nonfatal cardiovascular event rates among patients who 
had white-coat hypertension, sustained hypertension, or were normotensive. Investigators performed 24-hour 
ABPM on 1187 patients who had clinic blood pressures over 140/90 on three visits. They found that 228 
patients had white-coat hypertension, defined as mean ambulatory blood pressures below the 90th percentile 
of a normotensive population, and 959 patients had sustained hypertension. They followed these patients, 
along with 205 normotensive controls, for a mean of 3.2 years. Cardiovascular event rates did not differ 
significantly between normotensive and white-coat hypertension patients (P=.83; see Table ), but the 
difference in event-free survival between the sustained hypertension group and both the white-coat 
hypertension and normotensive groups was highly significant (P=.002).2 
In contrast, a recent 10-year longitudinal study of 146 normotensive people, 76 people with white-coat 
hypertension, and 344 with sustained hypertension showed that cardiovascular event rates were similar for 
patients with white-coat and sustained hypertension, and were significantly higher than in the normotensive 
group (P=.03 overall, P=.03 between white-coat hypertension and normotension and P=.01 between sustained 
hypertension and normotension).3 
One randomized trial evaluated outcomes of antihypertensive therapy for white-coat hypertension for patients 
aged >60 years. Ninety-nine patients with white-coat hypertension were identified on the basis of systolic blood 
pressure greater than 160 mm Hg in clinic and normal 24-hour ABPM and were randomized to either place-bo 
or drug therapy. Active treatment did not significantly lower ambulatory blood pressure in white-coat 
hypertension, but it did reduce blood pressure measured in clinic. After a year, medication produced an 
absolute reduction in cardiovascular events of 8.6%, and in stroke of 4.2%. Neither result was statistically 
significant due to the small sample size.4 
 
TABLE 
Cohort studies of patients with white-coat hypertension 
    Total number of events   
Patients Outcome NT WCH SH P value 
479 patients, 
mean age of 
641 
Cardiovascular 
events 
N/A 
15 
(11.9%) 
83 
(23.5%) 
P<.001 
1392 patients, 
mean age of 
512 
Cardiovascular 
events 
4 
(1.9%) 
3 (1.3%) 
37 
(5.3%) 
WCH: NT 
vs P=.83 
WCH vs 
SH: 
P<.0001 
566 patients, 
mean age of 
483 
Cardiovascular 
events 
10 
(6.8%) 
14 
(18.4%) 
56 
(16.3%) 
Overall 
P=.03 
NT vs 
WCH: 
P=.03 
NT vs SH: 
P=.01 
NT, normotensive; WCH, white-coat hypertension; SH, sustained hypertension 
  RECOMMENDATIONS FROM OTHERS 
The American College of Cardiology and American Academy of Family Physicians have made no specific 
recommendations about white-coat hypertension. The Blood Pressure Monitoring Task Force V concluded that 
a significant number of white-coat hypertension patients become truly hypertensive over years of follow-up.5 
Experts agree that patients with white-coat hypertension should be indefinitely monitored for the development 
of sustained hypertension.6 Treatment is not needed unless the patient has sustained hypertension, evidence 
of cardiovascular disease, or signs of target organ injury.7,8 Typically, expert opinion recommends confirming 
the diagnosis of white-coat hypertension with home blood pressure records or ambulatory blood pressure 
monitoring. 
CLINICAL COMMENTARY: 
White-coat hypertension represents one point along the 
continuum of hypertension 
 
Mark  B.  Stephens,  MD, MS 
Uniformed Services University, Bethesda, Md 
Unfortunately, the best available clinical evidence provides an unfulfilling answer to the question 
posed by this Clinical Inquiry. It requires inductive reasoning and logic to derive a treatment plan 
from the evidence presented. Perhaps it is because the diagnosis of white-coat hypertension 
remains poorly defined and clinically elusive. 
Nevertheless, application of the simple principle of “where there’s smoke, there’s fire” fits best here. 
Clinicians should be aware that white-coat hypertension represents one point along the continuum 
of hypertensive disease. When diagnosed, patients with white-coat hypertension should at a 
minimum be followed for associated morbidities and treated when systemic hypertension is 
identified. 
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